Entinostat D4

Entinostat D4 is a deuterated form of Entinostat, a small molecule drug being investigated for its potential use in cancer therapy. It is an orally administered, class I-selective histone deacetylase (HDAC) inhibitor that works by inhibiting the activity of HDAC enzymes, which are involved in the regulation of gene expression. By inhibiting these enzymes, Entinostat D4 is able to promote the expression of certain genes that are involved in the regulation of cell growth and differentiation. In preclinical studies, Entinostat D4 has demonstrated anti-tumor activity in a variety of cancer cell lines, including breast, lung, colon, and prostate cancer. It has also been shown to enhance the activity of other cancer therapies, such as chemotherapy and immunotherapy. Chemically, Entinostat D4 is a deuterated analog of Entinostat, which means that it contains four deuterium atoms instead of hydrogen atoms. The incorporation of deuterium into the molecule can improve its pharmacokinetic properties, such as its bioavailability and half-life, which can enhance its efficacy and reduce the risk of toxicity. Overall, Entinostat D4 is a promising drug candidate for the treatment of cancer, and ongoing clinical trials are currently underway to evaluate its safety and efficacy in humans.